NCT00482053 2018-05-14Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCTStanford UniversityPhase 2 Terminated3 enrolled 13 charts
NCT00588094 2015-12-04Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHLMemorial Sloan Kettering Cancer CenterPhase 2 Completed20 enrolled 6 charts